EMG
LKFT

Ellington Management Group’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Ellington Management Group’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,200
Closed -$455K – 623
2019
Q4 		$455K Buy
+2,200
New +$407K 0.1% 192
2019
Q2 		– Sell
-4,200
Closed -$495K – 653
2019
Q1 		$495K Buy
+4,200
New +$423K 0.09% 237

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Ellington Management Group's LKFT Position: Q1 2020 in Review

Ellington Management Group sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2020, closing a stake of 2,200 shares — an estimated $455K sold.

Ellington Management Group first reported a position in LKFT in Q1 2019 and held it in 2 quarters. The position peaked at $495K in Q1 2019. 140 funds tracked by Wall St. Rank hold LKFT as of Q1 2020.

  • Ellington Management Group reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2020 after selling out during the quarter.
  • Ellington Management Group sold 2,200 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2020, an estimated $455K.
  • Ellington Management Group first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2019 and held it in 2 quarters.
  • Ellington Management Group's Lakefront Biotherapeutics American Depositary Shares position peaked at $495K in Q1 2019.
  • 140 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.